Nucleic Acid News and Research

RSS

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

FDA approves DNA test to measure hepatitis B viral load

The U.S. Food and Drug Administration today approved the first nucleic acid test for hepatitis B virus (HBV) that measures the amount of viral DNA (viral load) in a patient's blood. Assessing a patient's viral load provides health care professionals with a highly sensitive method for gauging the progress of antiviral therapy in patients with chronic HBV infections.

5 Sep 2008

FDA clears non-invasive test to help manage heart transplant patients

The U.S. Food and Drug Administration has announced it has cleared for marketing a non-invasive test that uses molecular expression techniques to assist doctors in managing heart transplant patients post-surgery for potential organ rejection.

27 Aug 2008

Roche acquires Mirus to advance RNAi delivery research

Roche (Basel) and Mirus Bio Corporation (Madison, WI, USA) announced today that they have entered into a definitive agreement under which Roche will acquire Mirus Bio Corporation, a privately-owned US company based in Madison, Wisconsin, that focuses on the discovery and development of innovative nucleic acid based technologies, including a proprietary RNAi (Ribonucleic Acid interference) delivery platform.

22 Jul 2008

An inflamed response

Paul Martin, Professor of Cell Biology in the University of Bristol Departments of Physiology and Pharmacology, and Biochemistry, talked to Cherry Lewis about the discovery made in his lab that speeds up wound healing and reduces the size of the wound scar. She was interested not only in the discovery itself, but also in the processes and years of research that led up to it.

15 Jul 2008

Nanoparticle delivers antisense agent to tumors

A multifunctional drug delivery system consisting of a lipid-based nanoparticle, a standard anticancer drug, and a short nucleic acid designed to augment the activity of that drug has demonstrated the ability to treat drug-resistant tumor cells.

15 Jun 2008

Research reveals workings of anti-HIV drugs

Using ingenious molecular espionage, scientists have found how a single key enzyme, seemingly the Swiss Army knife in HIV's toolbox, differentiates and dynamically binds both DNA and RNA as part of the virus's fierce attack on host cells. The work is described this week (May 7) in the journal Nature.

8 May 2008

Scientists discover how reverse transcriptase molecules interact with the HIV genome

Using ingenious molecular espionage, scientists have found how a single key enzyme, seemingly the Swiss army knife in HIV's toolbox, differentiates and dynamically binds both DNA and RNA as part of the virus' fierce attack on host cells. The work is described this week in the journal Nature.

7 May 2008

Making GNA for nanotechnology

In the rapid and fast-growing world of nanotechnology, researchers are continually on the lookout for new building blocks to push innovation and discovery to scales much smaller than the tiniest speck of dust.

29 Apr 2008

Anticancer siRNA therapy advances, thanks to nanoparticles

Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.

28 Mar 2008

New study confirms that PROGENSA PCA3 can improve accuracy of prostate cancer diagnosis

New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.

20 Mar 2008

IRIS International completes study of 85 post-prostatectomy patients using investigational NADiA PSA assay

IRIS International Inc. has announced that its Iris Molecular Diagnostics (IMD) group has successfully completed a retrospective study of stored leftover serum of 85 post-prostatectomy patients, men who had their prostate removed due to prostate cancer, using its investigational NADiA (Nucleic Acid Detection ImmunoAssay) PSA Assay.

27 Feb 2008

Pre-eclampsia linked to herpes virus

Australian researchers have discovered a viral link which they believe may help explain high blood pressure during pregnancy (pre-eclampsia) and pre-term birth.

18 Feb 2008

Stanford researchers make first direct observation of 3-D molecule folding in real time

All the crucial proteins in our bodies must fold into complex shapes to do their jobs.

18 Feb 2008

New approach to gene therapy

RNA interference (RNAi) represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing the state-of-the-art and potential therapeutic applications of RNAi and microRNAs will begin with two review papers in the January 2008 issue (Volume 19, Number 1) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.

24 Jan 2008

Gene detection platform made from self-assembled DNA nanostructures

Scientists at Arizona State University's Biodesign Institute have developed the world's first gene detection platform made up entirely from self-assembled DNA nanostructures.

11 Jan 2008

RNA silences cancer suppressor gene

One way cancer arises is when tumor suppressor genes that normally keep cell growth in check are mysteriously turned off.

10 Jan 2008

FDA clears test for 12 specific respiratory viruses

The U.S. Food and Drug Administration has cleared for marketing a test that simultaneously detects and identifies 12 specific respiratory viruses.

4 Jan 2008

Personalized medicine will alter treatment of genetic disorders

One of the nation's pre-eminent genetic researchers, Eric Hoffman, PhD, of Children's Research Institute at Children's National Medical Center, predicts that in relatively short order, medicine's next innovation--individualized molecular therapies--will have the unprecedented ability to treat muscular dystrophies, and other disorders.

28 Dec 2007

Medical College of Georgia selected as RNA laboratory for worldwide diabetes study

The Medical College of Georgia Center for Biotechnology and Genomic Medicine has been selected to isolate RNA and DNA from the blood of thousands of children involved in a worldwide study of the causes of type 1 diabetes.

18 Dec 2007